儿童肺炎球菌疫苗接种策略比较:PCV20与PCV15及PCV13的动态模型分析
研究采用年龄结构 compartmental 动态传播模型,模拟美国儿童常规接种程序中PCV20相较于PCV15和PCV13的健康与经济影响。结论支持采用高价PCV20的儿童接种策略。
要点
- 动态模型支持美国儿童接种PCV20以降低疾病负担和医疗成本。
核心结论
- 儿童接种PCV20较PCV15或PCV13可减少肺炎球菌疾病负担并节省医疗成本,具健康与经济价值。
研究设计与样本
- 开发年龄结构 compartmental 动态传播模型,模拟美国肺炎链球菌传播,校准至历史侵袭性肺炎球菌疾病(IPD)发病率。
- 评估PCV20 vs PCV15和PCV13在美国儿童常规接种程序中的影响,假设肺炎球菌肺炎(PP)和中耳炎(OM)发病率与IPD成比例。
- 结局包括病例数、质量调整生命年(QALY)、直接医疗成本(2025 USD)和增量成本效果比,覆盖全美人口(328,239,522)10年时间范围。
主要发现
- PCV20较PCV15增加17,717 QALY,为绝对优势(成本节省且更有效)。
临床怎么用
- 公共卫生决策者可参考动态模型结果,优先考虑儿童常规接种PCV20以降低疾病负担和医疗成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Both 20-valent (PCV20) and 15-valent (PCV15) pneumococcal conjugate vaccines are recommended in the US pediatric immunization program. Static models previously have found PCV20 cost-effective compared to PCV15 and a 13-valent vaccine (PCV13). The objective of this study is to assess the health and economic impact of PCV20 compared to PCV15 or PCV13 using a dynamic transmission model (DTM). METHODS: An age-structured, compartmental DTM was developed to simulate the transmission dynamics of Streptococcus pneumoniae in the US, calibrated to historical invasive pneumococcal disease (IPD) incidence. The model estimated the impact of PCV20 versus PCV15 and PCV13 in the routine pediatric vaccination program in the US. Pneumococcal pneumonia (PP) and otitis media (OM) incidence were assumed a proportional relationship to IPD. Outcomes included disease cases, quality-adjusted life-years (QALYs), direct medical costs (2025 USD), and incremental cost-effectiveness ratio for the entire US population (328,239,522) over a 10-year horizon. RESULTS: Compared with PCV15, PCV20 pediatric vaccination averted 4.0 million disease cases (31,361 IPD, 0.889 million PP, and 3.1 million pneumococcal OM) with cost savings of $4.027 billion over 10 years. PCV20 resulted in an additional 17,717 QALY versus PCV15, thus PCV20 was dominant (cost saving and more effective) compared with PCV15. PCV20 was also dominant versus PCV13, with incremental cost savings of $5.940 billion and 26,099 additional QALY over 10 years. CONCLUSIONS: Pediatric PCV20 use is projected to reduce pneumococcal disease burden and healthcare costs in the US compared with PCV15 or PCV13. Results support the health and economic value of adopting a higher-valent pediatric vaccination approach using PCV20.
引用
- Wilson M, Althouse BM, Lucas A, et al. A comparative analysis of pediatric pneumococcal vaccination strategies: a dynamic model of PCV20 vs. PCV15 and PCV13. Vaccine. 2026. PMID: 41747336. doi:10.1016/j.vaccine.2026.128350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。